Amended Statement of Beneficial Ownership (sc 13d/a)
27 September 2022 - 7:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
POINT
BIOPHARMA GLOBAL INC.
(Name of Issuer)
Common stock, par value
$0.0001 per share
(Title of Class of Securities)
730541109
(CUSIP Number)
RA Capital Management, L.P.
200 Berkeley Street, 18th Floor
Boston, MA 02116
Telephone: 617.778.2500
Attn: Peter Kolchinsky
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
September 26, 2022
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 730541109
1 |
Names of Reporting Persons.
RA Capital Management, L.P. |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) |
¨ |
|
(b) |
¨ |
3 |
SEC
Use Only |
4 |
Source of Funds (See Instructions):
AF |
5 |
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
¨ |
6 |
Citizenship or Place of Organization. Delaware
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power
0 shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared Dispositive Power 0
shares
|
11 |
Aggregate Amount Beneficially Owned by Each
Reporting Person
0 shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in
Row (11)
0% |
|
14 |
Type of Reporting Person (See Instructions)
IA, PN |
|
|
|
|
|
CUSIP No. 730541109
1 |
Names of Reporting Persons.
Peter Kolchinsky |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) |
¨ |
|
(b) |
¨ |
3 |
SEC
Use Only |
4 |
Source of Funds (See Instructions):
AF |
5 |
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
¨ |
6 |
Citizenship or Place of Organization. United States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power
0 shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared Dispositive Power 0
shares
|
11 |
Aggregate Amount Beneficially Owned by Each
Reporting Person
0 shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in
Row (11)
0% |
|
14 |
Type of Reporting Person (See Instructions)
HC, IN
|
|
|
|
|
|
CUSIP No. 730541109
1 |
Names of Reporting Persons.
Rajeev Shah |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) |
¨ |
|
(b) |
¨ |
3 |
SEC
Use Only |
4 |
Source of Funds (See Instructions):
AF |
5 |
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
¨ |
6 |
Citizenship or Place of Organization. United States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power
0 shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared Dispositive Power 0
shares
|
11 |
Aggregate Amount Beneficially Owned by Each
Reporting Person
0 shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in
Row (11)
0% |
|
14 |
Type of Reporting Person (See Instructions)
HC, IN
|
|
|
|
|
|
CUSIP No. 730541109
1 |
Names of Reporting Persons.
RA Capital Healthcare Fund, L.P. |
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) |
¨ |
|
(b) |
¨ |
3 |
SEC
Use Only |
4 |
Source of Funds (See Instructions):
AF |
5 |
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
¨ |
6 |
Citizenship or Place of Organization. United States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power
0 shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared Dispositive Power 0
shares
|
11 |
Aggregate Amount Beneficially Owned by Each
Reporting Person
0 shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in
Row (11)
0% |
|
14 |
Type of Reporting Person (See Instructions)
PN
|
|
|
|
|
|
CUSIP No. 730541109
SCHEDULE 13D
Item 1. Security and Issuer
Item 1 of the Statement is hereby amended and
restated as follows:
This Amendment No. 4 amends and supplements
the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on June 30, 2021,
as amended by Amendment No. 1 filed on September 14, 2021, Amendment No. 2 filed on August 29, 2022, and Amendment
No. 3 filed on September 16, 2022 (the “Statement”) by RA Capital Management, L.P. (“RA Capital”), Peter
Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. (the “Fund”) with respect to the Common Stock of POINT Biopharma
Global Inc. (formerly known as Therapeutics Acquisition Corp.), a Delaware Corporation (the “Issuer”), which has its principal
executive offices at 4850 West 78th Street Indianapolis, IN. Unless otherwise defined herein, capitalized terms used in
this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information
in the Statement remains unchanged.
Item 2. Identity and Background
Item 2 of the Statement is hereby amended and
restated as follows:
(a) This Schedule 13D is being filed
on behalf of RA Capital, the Fund, Peter Kolchinsky, and Rajeev Shah. RA Capital, Dr. Kolchinsky, Mr. Shah, and the Fund are
collectively referred to herein as the “Reporting Persons.”
The Fund holds 0 shares, RA Capital Nexus Fund,
L.P. (the “Nexus Fund”) holds 0 shares, and 0 shares are held by a separately managed account (the “Account”).
RA Capital Healthcare Fund GP, LLC is the general
partner of the Fund and RA Capital Nexus Fund GP, LLC is the general partner of the Nexus Fund. The general partner of RA Capital is RA
Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment
adviser for the Fund, the Account, and the Nexus Fund, and may be deemed a beneficial owner, for purposes of Section 13(d) of
the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund, the Account, or the Nexus
Fund. The Fund, the Nexus Fund and the Account have delegated to RA Capital the sole power to vote and the sole power to dispose of all
securities held in their respective portfolios, including the shares of the Issuer’s Common Stock reported herein. Because the Fund,
the Nexus Fund and the Account have divested themselves of voting and investment power over the reported securities and may not revoke
that delegation on less than 61 days’ notice, the Fund, the Nexus Fund, and the Account disclaim beneficial ownership of the reported
securities for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported
securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial
owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital,
Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13D Statement other than
for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be
deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other
purpose.
CUSIP No. 730541109
(b) The address of the principal business
office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116.
(c) The Fund is a private investment vehicle. RA Capital provides
investment management services to the Fund. The principal occupation of Dr. Kolchinsky and Mr. Shah is investment management.
(d) During the last five years, none of
the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, none of
the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result
of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) See Item 6 of the cover pages.
Item 4. Purpose
of Transaction Item 4 of the Statement is hereby amended and supplemented as follows: The information set forth in Item 5 of
this Amendment No. 4 is incorporated by reference into this Item 4.
Item 5. Interest in Securities of the Issuer
(a) and (b) See Items 7-11 of the cover
pages and Item 2 above.
(c) The table set forth in Schedule A lists
the Reporting Persons’ transactions with respect to the Issuer’s securities for the past 60 days.
(d) Not applicable.
(e) On September 26, 2022 the reporting
persons ceased being owners of more than 5% of the issuer's outstanding common stock.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. Item 6 of the Statement is hereby amended and supplemented as follows:
The information set forth in Item 5 of this Amendment
No. 4 is incorporated by reference into this Item 6.
CUSIP No. 730541109
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: September 26,
2022
RA CAPITAL MANAGEMENT, L.P. |
|
|
|
By: |
/s/
Peter Kolchinsky |
|
|
Name: |
Peter Kolchinsky |
|
|
Title: |
Authorized Signatory |
|
|
|
PETER KOLCHINSKY |
|
|
|
/s/
Peter Kolchinsky |
|
|
|
RAJEEV SHAH |
|
|
|
/s/
Rajeev Shah |
|
|
|
RA CAPITAL HEALTHCARE FUND, L.P. |
|
|
|
By: |
RA Capital Healthcare Fund GP, LLC |
|
Its: |
General Partner |
|
|
|
|
By: |
/s/
Peter Kolchinsky |
|
|
Name: |
Peter Kolchinsky |
|
|
Title: |
Manager |
|
CUSIP No. 730541109
Schedule A
Type | |
Fund | |
Trade
Date | |
Quantity | |
Price | |
Short Sale | |
The Nexus Fund | |
7/28/22 | |
29,162 | |
$ | 7.56 | |
Short Sale | |
The Fund | |
7/28/22 | |
87,488 | |
$ | 7.56 | |
Short Sale | |
The Nexus Fund | |
7/29/22 | |
6,319 | |
$ | 7.35 | |
Short Sale | |
The Fund | |
7/29/22 | |
18,958 | |
$ | 7.35 | |
Short Sale | |
The Nexus Fund | |
8/1/22 | |
34 | |
$ | 7.60 | |
Short Sale | |
The Nexus Fund | |
8/1/22 | |
11,075 | |
$ | 7.46 | |
Short Sale | |
The Fund | |
8/1/22 | |
101 | |
$ | 7.60 | |
Short Sale | |
The Fund | |
8/1/22 | |
33,225 | |
$ | 7.46 | |
Short Sale | |
The Nexus Fund | |
8/2/22 | |
23,407 | |
$ | 7.51 | |
Short Sale | |
The Nexus Fund | |
8/2/22 | |
6,425 | |
$ | 7.35 | |
Short Sale | |
The Fund | |
8/2/22 | |
70,220 | |
$ | 7.51 | |
Short Sale | |
The Fund | |
8/2/22 | |
19,275 | |
$ | 7.35 | |
Short Sale | |
The Nexus Fund | |
8/3/22 | |
21,546 | |
$ | 7.74 | |
Short Sale | |
The Nexus Fund | |
8/3/22 | |
1,750 | |
$ | 7.84 | |
Short Sale | |
The Fund | |
8/3/22 | |
64,638 | |
$ | 7.74 | |
Short Sale | |
The Fund | |
8/3/22 | |
5,250 | |
$ | 7.84 | |
Short Sale | |
The Nexus Fund | |
8/4/22 | |
17,782 | |
$ | 7.78 | |
Short Sale | |
The Fund | |
8/4/22 | |
53,347 | |
$ | 7.78 | |
Short Sale | |
The Account | |
8/9/22 | |
5,342 | |
$ | 8.77 | |
Short Sale | |
The Account | |
8/9/22 | |
7,533 | |
$ | 8.89 | |
Short Sale | |
The Account | |
8/9/22 | |
946 | |
$ | 8.88 | |
Short Sale | |
The Account | |
8/9/22 | |
4,730 | |
$ | 8.86 | |
Short Sale | |
The Nexus Fund | |
8/9/22 | |
15,904 | |
$ | 8.77 | |
Short Sale | |
The Nexus Fund | |
8/9/22 | |
22,425 | |
$ | 8.89 | |
Short Sale | |
The Nexus Fund | |
8/9/22 | |
2,817 | |
$ | 8.88 | |
CUSIP No. 730541109
Short Sale | |
The Nexus Fund | |
8/9/22 | |
14,083 | |
$ | 8.86 | |
Short Sale | |
The Fund | |
8/9/22 | |
63,454 | |
$ | 8.77 | |
Short Sale | |
The Fund | |
8/9/22 | |
89,471 | |
$ | 8.89 | |
Short Sale | |
The Fund | |
8/9/22 | |
11,237 | |
$ | 8.88 | |
Short Sale | |
The Fund | |
8/9/22 | |
56,187 | |
$ | 8.86 | |
Short Sale | |
The Account | |
8/10/22 | |
2,298 | |
$ | 9.10 | |
Short Sale | |
The Account | |
8/10/22 | |
17,307 | |
$ | 9.01 | |
Short Sale | |
The Nexus Fund | |
8/10/22 | |
6,843 | |
$ | 9.10 | |
Short Sale | |
The Nexus Fund | |
8/10/22 | |
51,524 | |
$ | 9.01 | |
Short Sale | |
The Fund | |
8/10/22 | |
27,299 | |
$ | 9.10 | |
Short Sale | |
The Fund | |
8/10/22 | |
205,569 | |
$ | 9.01 | |
Short Sale | |
The Account | |
8/12/22 | |
2,081 | |
$ | 8.76 | |
Short Sale | |
The Nexus Fund | |
8/12/22 | |
6,197 | |
$ | 8.76 | |
Short Sale | |
The Fund | |
8/12/22 | |
24,722 | |
$ | 8.76 | |
Short Sale | |
The Account | |
8/15/22 | |
501 | |
$ | 8.81 | |
Short Sale | |
The Nexus Fund | |
8/15/22 | |
1,490 | |
$ | 8.81 | |
Short Sale | |
The Fund | |
8/15/22 | |
5,945 | |
$ | 8.81 | |
Short Sale | |
The Account | |
8/18/22 | |
1,658 | |
$ | 8.76 | |
Short Sale | |
The Nexus Fund | |
8/18/22 | |
4,936 | |
$ | 8.76 | |
Short Sale | |
The Fund | |
8/18/22 | |
19,692 | |
$ | 8.76 | |
Short Sale | |
The Account | |
8/19/22 | |
1,637 | |
$ | 8.91 | |
Short Sale | |
The Account | |
8/19/22 | |
22,075 | |
$ | 8.79 | |
Short Sale | |
The Nexus Fund | |
8/19/22 | |
4,873 | |
$ | 8.91 | |
Short Sale | |
The Nexus Fund | |
8/19/22 | |
65,720 | |
$ | 8.79 | |
Short Sale | |
The Fund | |
8/19/22 | |
19,444 | |
$ | 8.91 | |
Short Sale | |
The Fund | |
8/19/22 | |
262,205 | |
$ | 8.79 | |
Short Sale | |
The Account | |
8/22/22 | |
2,586 | |
$ | 8.90 | |
Short Sale | |
The Account | |
8/22/22 | |
3,153 | |
$ | 8.79 | |
CUSIP No. 730541109
Short Sale | |
The Account | |
8/22/22 | |
6,307 | |
$ | 8.87 | |
Short Sale | |
The Nexus Fund | |
8/22/22 | |
7,699 | |
$ | 8.90 | |
Short Sale | |
The Nexus Fund | |
8/22/22 | |
9,389 | |
$ | 8.79 | |
Short Sale | |
The Nexus Fund | |
8/22/22 | |
18,777 | |
$ | 8.87 | |
Short Sale | |
The Fund | |
8/22/22 | |
30,715 | |
$ | 8.90 | |
Short Sale | |
The Fund | |
8/22/22 | |
37,458 | |
$ | 8.79 | |
Short Sale | |
The Fund | |
8/22/22 | |
74,916 | |
$ | 8.87 | |
Short Sale | |
The Account | |
8/23/22 | |
1,577 | |
$ | 8.81 | |
Short Sale | |
The Account | |
8/23/22 | |
3,153 | |
$ | 8.93 | |
Short Sale | |
The Account | |
8/23/22 | |
6,428 | |
$ | 9.13 | |
Short Sale | |
The Nexus Fund | |
8/23/22 | |
4,694 | |
$ | 8.81 | |
Short Sale | |
The Nexus Fund | |
8/23/22 | |
9,389 | |
$ | 8.93 | |
Short Sale | |
The Nexus Fund | |
8/23/22 | |
19,137 | |
$ | 9.13 | |
Short Sale | |
The Fund | |
8/23/22 | |
18,729 | |
$ | 8.81 | |
Short Sale | |
The Fund | |
8/23/22 | |
37,458 | |
$ | 8.93 | |
Short Sale | |
The Fund | |
8/23/22 | |
76,350 | |
$ | 9.13 | |
Short Sale | |
The Account | |
8/24/22 | |
13,182 | |
$ | 9.57 | |
Short Sale | |
The Account | |
8/24/22 | |
4,730 | |
$ | 9.50 | |
Short Sale | |
The Nexus Fund | |
8/24/22 | |
39,244 | |
$ | 9.57 | |
Short Sale | |
The Nexus Fund | |
8/24/22 | |
14,083 | |
$ | 9.50 | |
Short Sale | |
The Fund | |
8/24/22 | |
156,574 | |
$ | 9.57 | |
Short Sale | |
The Fund | |
8/24/22 | |
56,187 | |
$ | 9.50 | |
Short Sale | |
The Account | |
8/25/22 | |
3,313 | |
$ | 10.24 | |
Short Sale | |
The Account | |
8/25/22 | |
8,313 | |
$ | 9.83 | |
Short Sale | |
The Nexus Fund | |
8/25/22 | |
9,863 | |
$ | 10.24 | |
Short Sale | |
The Nexus Fund | |
8/25/22 | |
24,748 | |
$ | 9.83 | |
Short Sale | |
The Fund | |
8/25/22 | |
39,351 | |
$ | 10.24 | |
Short Sale | |
The Fund | |
8/25/22 | |
98,739 | |
$ | 9.83 | |
CUSIP No. 730541109
Short Sale | |
The Account | |
8/26/22 | |
3,135 | |
$ | 10.00 | |
Short Sale | |
The Account | |
8/26/22 | |
2,710 | |
$ | 10.18 | |
Short Sale | |
The Nexus Fund | |
8/26/22 | |
9,332 | |
$ | 10.00 | |
Short Sale | |
The Nexus Fund | |
8/26/22 | |
8,068 | |
$ | 10.18 | |
Short Sale | |
The Fund | |
8/26/22 | |
37,233 | |
$ | 10.00 | |
Short Sale | |
The Fund | |
8/26/22 | |
32,190 | |
$ | 10.18 | |
Short Sale | |
The Account | |
8/29/22 | |
4,500 | |
$ | 10.27 | |
Short Sale | |
The Account | |
8/29/22 | |
5,180 | |
$ | 10.21 | |
Short Sale | |
The Nexus Fund | |
8/29/22 | |
13,398 | |
$ | 10.27 | |
Short Sale | |
The Nexus Fund | |
8/29/22 | |
15,423 | |
$ | 10.21 | |
Short Sale | |
The Fund | |
8/29/22 | |
53,452 | |
$ | 10.27 | |
Short Sale | |
The Fund | |
8/29/22 | |
61,533 | |
$ | 10.21 | |
Short Sale | |
The Account | |
8/30/22 | |
10 | |
$ | 10.41 | |
Short Sale | |
The Nexus Fund | |
8/30/22 | |
30 | |
$ | 10.41 | |
Short Sale | |
The Fund | |
8/30/22 | |
119 | |
$ | 10.41 | |
Short Sale | |
The Account | |
8/31/22 | |
627 | |
$ | 9.83 | |
Short Sale | |
The Account | |
8/31/22 | |
3,488 | |
$ | 9.70 | |
Short Sale | |
The Nexus Fund | |
8/31/22 | |
1,866 | |
$ | 9.83 | |
Short Sale | |
The Nexus Fund | |
8/31/22 | |
10,384 | |
$ | 9.70 | |
Short Sale | |
The Fund | |
8/31/22 | |
7,446 | |
$ | 9.83 | |
Short Sale | |
The Fund | |
8/31/22 | |
41,428 | |
$ | 9.70 | |
Short Sale | |
The Account | |
9/1/22 | |
906 | |
$ | 10.00 | |
Short Sale | |
The Nexus Fund | |
9/1/22 | |
2,696 | |
$ | 10.00 | |
Short Sale | |
The Fund | |
9/1/22 | |
10,756 | |
$ | 10.00 | |
Short Sale | |
The Account | |
9/2/22 | |
3,217 | |
$ | 10.11 | |
Short Sale | |
The Account | |
9/2/22 | |
2,321 | |
$ | 10.23 | |
Short Sale | |
The Nexus Fund | |
9/2/22 | |
9,576 | |
$ | 10.11 | |
Short Sale | |
The Nexus Fund | |
9/2/22 | |
6,910 | |
$ | 10.23 | |
CUSIP No. 730541109
Short Sale | |
The Fund | |
9/2/22 | |
38,207 | |
$ | 10.11 | |
Short Sale | |
The Fund | |
9/2/22 | |
27,569 | |
$ | 10.23 | |
Short Sale | |
The Account | |
9/6/22 | |
5,487 | |
$ | 7.53 | |
Short Sale | |
The Account | |
9/6/22 | |
43,405 | |
$ | 8.13 | |
Short Sale | |
The Account | |
9/6/22 | |
6,911 | |
$ | 7.28 | |
Short Sale | |
The Nexus Fund | |
9/6/22 | |
16,336 | |
$ | 7.53 | |
Short Sale | |
The Nexus Fund | |
9/6/22 | |
129,224 | |
$ | 8.13 | |
Short Sale | |
The Nexus Fund | |
9/6/22 | |
20,576 | |
$ | 7.28 | |
Short Sale | |
The Fund | |
9/6/22 | |
65,177 | |
$ | 7.53 | |
Short Sale | |
The Fund | |
9/6/22 | |
515,571 | |
$ | 8.13 | |
Short Sale | |
The Fund | |
9/6/22 | |
82,094 | |
$ | 7.28 | |
Short Sale | |
The Account | |
9/7/22 | |
14,695 | |
$ | 8.20 | |
Short Sale | |
The Account | |
9/7/22 | |
6,307 | |
$ | 7.97 | |
Short Sale | |
The Account | |
9/7/22 | |
18,486 | |
$ | 7.64 | |
Short Sale | |
The Nexus Fund | |
9/7/22 | |
43,751 | |
$ | 8.20 | |
Short Sale | |
The Nexus Fund | |
9/7/22 | |
18,777 | |
$ | 7.97 | |
Short Sale | |
The Nexus Fund | |
9/7/22 | |
55,036 | |
$ | 7.64 | |
Short Sale | |
The Fund | |
9/7/22 | |
174,554 | |
$ | 8.20 | |
Short Sale | |
The Fund | |
9/7/22 | |
74,916 | |
$ | 7.97 | |
Short Sale | |
The Fund | |
9/7/22 | |
219,580 | |
$ | 7.64 | |
Short Sale | |
The Account | |
9/8/22 | |
1,892 | |
$ | 8.50 | |
Short Sale | |
The Account | |
9/8/22 | |
3,232 | |
$ | 8.67 | |
Short Sale | |
The Account | |
9/8/22 | |
3,828 | |
$ | 8.64 | |
Short Sale | |
The Nexus Fund | |
9/8/22 | |
5,633 | |
$ | 8.50 | |
Short Sale | |
The Nexus Fund | |
9/8/22 | |
9,622 | |
$ | 8.67 | |
Short Sale | |
The Nexus Fund | |
9/8/22 | |
11,398 | |
$ | 8.64 | |
Short Sale | |
The Fund | |
9/8/22 | |
22,475 | |
$ | 8.50 | |
Short Sale | |
The Fund | |
9/8/22 | |
38,391 | |
$ | 8.67 | |
CUSIP No. 730541109
Short Sale | |
The Fund | |
9/8/22 | |
45,474 | |
$ | 8.64 | |
Short Sale | |
The Account | |
9/9/22 | |
1,364 | |
$ | 8.66 | |
Short Sale | |
The Account | |
9/9/22 | |
4,730 | |
$ | 8.50 | |
Short Sale | |
The Nexus Fund | |
9/9/22 | |
4,062 | |
$ | 8.66 | |
Short Sale | |
The Nexus Fund | |
9/9/22 | |
14,083 | |
$ | 8.50 | |
Short Sale | |
The Fund | |
9/9/22 | |
16,205 | |
$ | 8.66 | |
Short Sale | |
The Fund | |
9/9/22 | |
56,187 | |
$ | 8.50 | |
Short Sale | |
The Account | |
9/12/22 | |
16,714 | |
$ | 9.82 | |
Short Sale | |
The Account | |
9/12/22 | |
22,864 | |
$ | 9.92 | |
Short Sale | |
The Nexus Fund | |
9/12/22 | |
49,760 | |
$ | 9.82 | |
Short Sale | |
The Nexus Fund | |
9/12/22 | |
68,067 | |
$ | 9.92 | |
Short Sale | |
The Fund | |
9/12/22 | |
198,526 | |
$ | 9.82 | |
Short Sale | |
The Fund | |
9/12/22 | |
271,569 | |
$ | 9.92 | |
Short Sale | |
The Account | |
9/14/22 | |
6,118 | |
$ | 8.84 | |
Short Sale | |
The Account | |
9/14/22 | |
14,568 | |
$ | 8.94 | |
Short Sale | |
The Nexus Fund | |
9/14/22 | |
18,214 | |
$ | 8.84 | |
Short Sale | |
The Nexus Fund | |
9/14/22 | |
43,368 | |
$ | 8.94 | |
Short Sale | |
The Fund | |
9/14/22 | |
72,668 | |
$ | 8.84 | |
Short Sale | |
The Fund | |
9/14/22 | |
173,026 | |
$ | 8.94 | |
Cover | |
The Fund | |
9/26/22 | |
6,748,048 | |
$ | 8.26 | |
Sell | |
The Fund | |
9/26/22 | |
6,748,048 | |
$ | 8.26 | |
Cover | |
The Nexus Fund | |
9/26/22 | |
1,000,000 | |
$ | 8.26 | |
Sell | |
The Nexus Fund | |
9/26/22 | |
1,000,000 | |
$ | 8.26 | |
Cover | |
The Account | |
9/26/22 | |
315,545 | |
$ | 8.26 | |
Sell | |
The Account | |
9/26/22 | |
315,545 | |
$ | 8.26 | |
Cover | |
The Nexus Fund | |
9/26/22 | |
939,425 | |
$ | 8.26 | |
Sell | |
The Nexus Fund | |
9/26/22 | |
939,425 | |
$ | 8.26 | |
Therapeutics Acquisition (NASDAQ:TXAC)
Historical Stock Chart
From May 2024 to Jun 2024
Therapeutics Acquisition (NASDAQ:TXAC)
Historical Stock Chart
From Jun 2023 to Jun 2024